Clinical Trial Update: Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reports pharmacology results for VX-745, a p38 MAP kinase inhibitor, studied in mild cognitive impairment due to Alzheimer's dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• VX-745 (VX-745)

Snippet

Sponsor: EIP Pharma Inc | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-04-03